Advertisement

Viral Vectors: A Wide Range of Choices and High Levels of Service

Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 178)

Abstract

Viruses are intracellular parasites with simple DNA or RNA genomes. Virus life revolves around three steps: infection of a host cell, replication of its genome within the host cell environment, and formation of new virions; this process is often but not always associated with pathogenic effects against the host organism. Since the mid-1980s, the main goal of viral vectorology has been to develop recombinant viral vectors for long-term gene delivery to mammalian cells, with minimal associated toxicity. Today, several viral vector systems are close to achieving this aim, providing stable transgenic expression in many different cell types and tissues. Here we review application characteristics of four vector systems, derived from adeno-associated viruses, adenoviruses, retroviruses and herpes simplex virus-1, for in vivo gene delivery. We discuss the transfer capacity of the expression vectors, the stability of their transgenic expression, the tropism of the recombinant viruses, the likelihood of induction of immunotoxicity, and the ease (or difficulty) of the virus production. In the end, we discuss applications of these vectors for delivery of three molecular systems for conditional mutagenesis, two for inducible transcriptional control of transgenic expression (the tet and the dimerizer systems), and the third one for inducible control of endogenous gene expression based on RNA interference.

Keywords

Recombinant viral vectors Gene delivery Conditional gene expression Conditional gene knock-down 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Apparailly F, Millet V, Noel D, Jacquet C, Sany J, Jorgensen C (2002) Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 13:1179–1188PubMedCrossRefGoogle Scholar
  2. Auricchio A, Gao GP, Yu QC, Raper S, Rivera VM, Clackson T, Wilson JM (2002a) Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Ther 9:963–971PubMedCrossRefGoogle Scholar
  3. Auricchio A, Rivera VM, Clackson T, O’Connor EE, Maguire AM, Tolentino MJ, Bennett J, Wilson JM (2002b) Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 6:238–242PubMedCrossRefGoogle Scholar
  4. Bantounas I, Phylactou LA, Uney JB (2004) RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33:545–557PubMedCrossRefGoogle Scholar
  5. Baskar JF, Smith PP, Nilaver G, Jupp RA, Hoffmann S, Peffer NJ, Tenney DJ, Colberg-Poley AM, Ghazal P, Nelson JA (1996) The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol 70:3207–3214PubMedGoogle Scholar
  6. Bohl D, Salvetti A, Moullier P, Heard JM (1998) Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 92:1512–1517PubMedGoogle Scholar
  7. Bowers WJ, Olschowka JA, Federoff HJ (2003) Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther 10:941–945PubMedCrossRefGoogle Scholar
  8. Büchen-Osmond C (2001) The Universal Virus Database of the International Committee on Taxonomy of Viruses (ICTVdB): ≥http://www.ncbi.nlm.nih.gov/ICTVdb/index.htm. Cited 15 June 2006Google Scholar
  9. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 90:8033–8037PubMedCrossRefGoogle Scholar
  10. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE (2000) Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2:619–623PubMedCrossRefGoogle Scholar
  11. Chen Y, Stamatoyannopoulos G, Song CZ (2003) Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 63:4801–4804PubMedGoogle Scholar
  12. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Joussemet B, Bujard H, Samulski RJ, Favre D, Moullier P (2004) Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther 9:410–418PubMedCrossRefGoogle Scholar
  13. Clark KR, Liu X, McGrath JP, Johnson PR (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 10:1031–1039PubMedCrossRefGoogle Scholar
  14. Davidson BL, Harper SQ (2005) Viral delivery of recombinant short hairpin RNAs. Methods Enzymol 392:145–173PubMedGoogle Scholar
  15. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97:3428–3432PubMedCrossRefGoogle Scholar
  16. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA (2003) Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9:1306–1312PubMedCrossRefGoogle Scholar
  17. Dittgen T, Nimmerjahn A, Komai S, Licznerski P, Waters J, Margrie TW, Helmchen F, Denk W, Brecht M, Osten P (2004) Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proc Natl Acad Sci U S A 101:18206–18211PubMedCrossRefGoogle Scholar
  18. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463–8471PubMedGoogle Scholar
  19. Fitzsimons HL, McKenzie JM, During MJ (2001) Insulators coupled to a minimal bidirectional tet cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain. Gene Ther 8:1675–1681PubMedCrossRefGoogle Scholar
  20. Fotaki ME, Pink JR, Mous J (1997) Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer. Gene Ther 4:901–908PubMedCrossRefGoogle Scholar
  21. Frankel AD, Young JA (1998) HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67:1–25PubMedCrossRefGoogle Scholar
  22. Fussenegger M, Morris RP, Fux C, Rimann M, von Stockar B, Thompson CJ, Bailey JE (2000) Streptogramin-based gene regulation systems for mammalian cells. Nat Biotechnol 18:1203–1208PubMedCrossRefGoogle Scholar
  23. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H, Galun E, Gazit Z, Jorgensen C, Gazit D (2004) Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 9:587–595PubMedCrossRefGoogle Scholar
  24. Gaggar A, Shayakhmetov DM, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408–1412PubMedCrossRefGoogle Scholar
  25. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99:11854–11859PubMedCrossRefGoogle Scholar
  26. Geller AI, Breakefield XO (1988) A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241:1667–1669PubMedCrossRefGoogle Scholar
  27. Gilbert R, Dudley RW, Liu AB, Petrof BJ, Nalbantoglu J, Karpati G (2003) Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet 12:1287–1299PubMedCrossRefGoogle Scholar
  28. Goins WF, Lee KA, Cavalcoli JD, O’Malley ME, DeKosky ST, Fink DJ, Glorioso JC (1999) Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J Virol 73:519–532PubMedGoogle Scholar
  29. Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 89:5547–5551PubMedCrossRefGoogle Scholar
  30. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766–1769PubMedCrossRefGoogle Scholar
  31. Grimm D, Kay MA (2003) From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3:281–304PubMedCrossRefGoogle Scholar
  32. Grimm D, Kern A, Rittner K, Kleinschmidt JA (1998) Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 9:2745–2760PubMedGoogle Scholar
  33. Grimm D, Kay MA, Kleinschmidt JA (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 7:839–850PubMedCrossRefGoogle Scholar
  34. Haberman RP, McCown TJ, Samulski RJ (1998) Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 5:1604–1611PubMedCrossRefGoogle Scholar
  35. Halbert CL, Allen JM, Miller AD (2001) Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 75:6615–6624PubMedCrossRefGoogle Scholar
  36. Hauck B, Chen L, Xiao W (2003) Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 7:419–425PubMedCrossRefGoogle Scholar
  37. Hosono T, Mizuguchi H, Katayama K, Xu ZL, Sakurai F, Ishii-Watabe A, Kawabata K, Yamaguchi T, Nakagawa S, Mayumi T, Hayakawa T (2004) Adenovirus vector-mediated doxycycline-inducible RNA interference. Hum Gene Ther 15:813–819PubMedCrossRefGoogle Scholar
  38. Jiang L, Rampalli S, George D, Press C, Bremer EG, O’Gorman MR, Bohn MC (2004) Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR. Gene Ther 11:1057–1067PubMedCrossRefGoogle Scholar
  39. Kafri T, van Praag H, Gage FH, Verma IM (2000) Lentiviral vectors: regulated gene expression. Mol Ther 1:516–521PubMedCrossRefGoogle Scholar
  40. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L (2001) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 98:13282–13287PubMedCrossRefGoogle Scholar
  41. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D (2002) Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295:868–872PubMedCrossRefGoogle Scholar
  42. Markusic D, Oude-Elferink R, Das AT, Berkhout B, Seppen J (2005) Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res 33:e63PubMedCrossRefGoogle Scholar
  43. Martin KR, Klein RL, Quigley HA (2002) Gene delivery to the eye using adeno-associated viral vectors. Methods 28:267–275PubMedCrossRefGoogle Scholar
  44. Matsukura S, Jones PA, Takai D (2003) Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 31:e77PubMedCrossRefGoogle Scholar
  45. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P (1998) Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5:938–945PubMedCrossRefGoogle Scholar
  46. Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, Carter EE, Barber RD, Baban DF, Kingsman SM, Kingsman AJ, O’Malley K, Mitrophanous KA (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 10:2109–2121PubMedCrossRefGoogle Scholar
  47. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ (2003) Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10:2112–2118PubMedCrossRefGoogle Scholar
  48. McCarty DM, Young SM Jr, Samulski RJ (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38:819–845PubMedCrossRefGoogle Scholar
  49. McConnell MJ, Imperiale MJ (2004) Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15:1022–1033PubMedCrossRefGoogle Scholar
  50. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431:343–349PubMedCrossRefGoogle Scholar
  51. Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, Mazarakis N (1999) Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 6:1808–1818PubMedCrossRefGoogle Scholar
  52. Miyagishi M, Taira K (2002) Development and application of siRNA expression vector. Nucleic Acids Res Suppl:113–114Google Scholar
  53. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72:8150–8157PubMedGoogle Scholar
  54. Mizuguchi H, Hayakawa T (2004) Targeted adenovirus vectors. Hum Gene Ther 15:1034–1044PubMedCrossRefGoogle Scholar
  55. Muruve DA (2004) The innate immune response to adenovirus vectors. Hum Gene Ther 15:1157–1166PubMedCrossRefGoogle Scholar
  56. Nakai H, Storm TA, Kay MA (2000) Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 18:527–532PubMedCrossRefGoogle Scholar
  57. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267PubMedCrossRefGoogle Scholar
  58. Ohkawa J, Taira K (2000) Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter. Hum Gene Ther 11:577–585PubMedCrossRefGoogle Scholar
  59. Pages JC, Bru T (2004) Toolbox for retrovectorologists. J Gene Med 6[Suppl 1]: S67–S82PubMedCrossRefGoogle Scholar
  60. Palmer D, Ng P (2003) Improved system for helper-dependent adenoviral vector production. Mol Ther 8:846–852PubMedCrossRefGoogle Scholar
  61. Palmer DJ, Ng P (2005) Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther 16:1–16PubMedCrossRefGoogle Scholar
  62. Paterna JC, Büeler H (2002) Recombinant adeno-associated virus vector design and gene expression in the mammalian brain. Methods 28:208–218PubMedCrossRefGoogle Scholar
  63. Pfeifer A (2004) Lentiviral transgenesis. Transgenic Res 13:513–522PubMedCrossRefGoogle Scholar
  64. Poeschla EM (2003) Non-primate lentiviral vectors. Curr Opin Mol Ther 5:529–540PubMedGoogle Scholar
  65. Poeschla EM, Wong-Staal F, Looney DJ (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4:354–357PubMedCrossRefGoogle Scholar
  66. Pollock R, Clackson T (2002) Dimerizer-regulated gene expression. Curr Opin Biotechnol 13:459–467PubMedCrossRefGoogle Scholar
  67. Pollock R, Issner R, Zoller K, Natesan S, Rivera VM, Clackson T (2000) Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci U S A 97:13221–13226PubMedCrossRefGoogle Scholar
  68. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76:791–801PubMedCrossRefGoogle Scholar
  69. Regulier E, Trottier Y, Perrin V, Aebischer P, Deglon N (2003) Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Hum Mol Genet 12:2827–2836PubMedCrossRefGoogle Scholar
  70. Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T, Magari SR, Phillips T, Courage NL, Cerasoli F Jr, Holt DA, Gilman M (1996) A humanized system for pharmacologic control of gene expression. Nat Med 2:1028–1032PubMedCrossRefGoogle Scholar
  71. Rivera VM, Ye X, Courage NL, Sachar J, Cerasoli F Jr, Wilson JM, Gilman M (1999) Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci U S A 96:8657–8662PubMedCrossRefGoogle Scholar
  72. Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C (1998) Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 9:2787–2794PubMedGoogle Scholar
  73. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA (2001) Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3:591–601PubMedCrossRefGoogle Scholar
  74. Salucci V, Scarito A, Aurisicchio L, Lamartina S, Nicolaus G, Giampaoli S, Gonzalez-Paz O, Toniatti C, Bujard H, Hillen W, Ciliberto G, Palombo F (2002) Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Ther 9:1415–1421PubMedCrossRefGoogle Scholar
  75. Samaniego LA, Neiderhiser L, DeLuca NA (1998) Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 72:3307–3320PubMedGoogle Scholar
  76. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S (1998) Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 18:180–183PubMedCrossRefGoogle Scholar
  77. Shah AC, Benos D, Gillespie GY, Markert JM (2003) Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 65:203–226PubMedCrossRefGoogle Scholar
  78. Shevtsova Z, Malik JM, Michel U, Bahr M, Kugler S (2005) Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 90:53–59PubMedCrossRefGoogle Scholar
  79. Spaete RR, Frenkel N(1982) The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30:295–304PubMedCrossRefGoogle Scholar
  80. Stavropoulos TA, Strathdee CA (1998) An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 72:7137–7143PubMedGoogle Scholar
  81. Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438–1445PubMedGoogle Scholar
  82. Sun L, Li J, Xiao X (2000) Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 6:599–602PubMedCrossRefGoogle Scholar
  83. Tenenbaum L, Chtarto A, Lehtonen E, Velu T, Brotchi J, Levivier M (2004) Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med 6[Suppl 1]:S212–S222PubMedCrossRefGoogle Scholar
  84. Tuschl T (2002) Expanding small RNA interference. Nat Biotechnol 20:446–448PubMedCrossRefGoogle Scholar
  85. Unsinger J, Kroger A, Hauser H, Wirth D (2001) Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes. Mol Ther 4:484–489PubMedCrossRefGoogle Scholar
  86. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D, Holstege FC, Brummelkamp TR, Agami R, Clevers H (2003) Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 4:609–615PubMedCrossRefGoogle Scholar
  87. Vigna E, Cavalieri S, Ailles L, Geuna M, Loew R, Bujard H, Naldini L (2002) Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther 5:252–261PubMedCrossRefGoogle Scholar
  88. Vigna E, Amendola M, Benedicenti F, Simmons AD, Follenzi A, Naldini L (2005) Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. Mol Ther 11:763–775PubMedCrossRefGoogle Scholar
  89. Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y (2001) An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 19:1067–1070PubMedCrossRefGoogle Scholar
  90. Wang S, Petravicz J, Breakefield XO (2003) Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol Ther 7:790–800PubMedCrossRefGoogle Scholar
  91. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X (2003) Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 10:2105–2111PubMedCrossRefGoogle Scholar
  92. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23:321–328PubMedCrossRefGoogle Scholar
  93. Weber W, Fussenegger M (2004) Approaches for trigger-inducible viral transgene regulation in gene-based tissue engineering. Curr Opin Biotechnol 15:383–391PubMedCrossRefGoogle Scholar
  94. Wiznerowicz M, Trono D (2003) Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 77:8957–8961PubMedCrossRefGoogle Scholar
  95. Wiznerowicz M, Trono D (2005) Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol 23:42–47PubMedCrossRefGoogle Scholar
  96. Xiao X, Li J, Samulski RJ (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72:2224–2232PubMedGoogle Scholar
  97. Yan Z, Zhang Y, Duan D, Engelhardt JF (2000) Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 97:6716–6721PubMedCrossRefGoogle Scholar
  98. Ye X, Rivera VM, Zoltick P, Cerasoli F Jr, Schnell MA, Gao G, Hughes JV, Gilman M, Wilson JM (1999) Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283:88–91PubMedCrossRefGoogle Scholar
  99. Yee JK, Friedmann T, Burns JC (1994) Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43:99–112PubMedGoogle Scholar
  100. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF, Gilboa E (1986) Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A 83:3194–3198PubMedCrossRefGoogle Scholar
  101. Zolotukhin S (2005) Production of recombinant adeno-associated virus vectors. Hum Gene Ther 16:551–557PubMedCrossRefGoogle Scholar
  102. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6:973–985PubMedCrossRefGoogle Scholar
  103. Zou L, Yuan X, Zhou H, Lu H, Yang K (2001) Helper-dependent adenoviral vector-mediated gene transfer in aged rat brain. Hum Gene Ther 12:181–191PubMedCrossRefGoogle Scholar
  104. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871–875PubMedCrossRefGoogle Scholar
  105. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873–9880PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  1. 1.Department of Molecular NeurobiologyMax Planck Institute for Medical ResearchHeidelbergGermany
  2. 2.Department of Physiology, Feinberg School of MedicineNorthwestern UniversityChicagoUSA

Personalised recommendations